^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Published date:
12/06/2020
Excerpt:
...141 patients were enrolled and treated with daily oral ibrutinib (420 mg or 560 mg) plus intravenous nivolumab...Per GEP, the most upregulated genes in responders were LEF1 and BTLA (overall), and CRTAM (germinal center B-cell–like DLBCL)...
DOI:
10.1016/j.tranon.2020.100977